NEW YORK (
) hit a new 52-week high Wednesday as it is currently trading at $12.76, above its previous 52-week high of $12.75 with 158,525 shares traded as of 1:34 p.m. ET. Average volume has been 461,700 shares over the past 30 days.
Endologix has a market cap of $713 million and is part of the
industry. Shares are up 7.1% year to date as of the close of trading on Tuesday.
Endologix, Inc. develops, manufactures, markets, and sells devices for treatments of aortic disorders.
- Sign up for TheStreet's FREE Dividend and Income Investor Newsletter
TheStreet Ratings rates Endologix as a
. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and weak operating cash flow. You can view the full
52-week high stocks
or get investment ideas from our